Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azelastine hydrochloride + fluticasone propionate (Apotex Inc.)
- Development stage
- Unknown
- Lead developer
- Meda
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Developed by Apotex, this is a generic nasal spray formulation combining azelastine hydrochloride and fluticasone propionate. It is a bioequivalent version of the branded product Dymista, indicated for the treatment of seasonal allergic rhinitis in patients 6 years of age and older. The combination therapy utilizes two distinct mechanisms: azelastine hydrochloride acts as a second-generation H1-receptor antagonist that blocks histamine and inhibits mast cell degranulation, while fluticasone propionate is a synthetic corticosteroid that binds to glucocorticoid receptors to exert potent anti-inflammatory effects. Together, these components provide comprehensive relief from nasal symptoms such as congestion, sneezing, and itching.
- Brand names
- Dymista
- Other names
- azelastine hydrochloride and fluticasone propionate nasal sprayApotex azelastine/fluticasone
02
Targets
GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on azelastine hydrochloride + fluticasone propionate (Apotex Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azelastine hydrochloride + fluticasone propionate (Apotex Inc.).